Biogen Inc
Research Biogen Inc (BIIB) on Bullrun: valuation model: 5.5% undervalued, market cap USD 31.98B, P/E 23.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIIB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal5.5% undervalued
- Market capUSD 31.98B
- P/E23.2
- Financial periodFY2025
- RevenueUSD 9.89B
- Revenue growth2.2%
- Net incomeUSD 1.29B
- Free cash flowUSD 2.05B
- Gross margin75.7%
Valuation Snapshot
Bullrun's latest valuation model marks Biogen Inc as 5.5% undervalued; latest market cap is USD 31.98B; P/E is 23.2.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA;
Frequently asked questions
Is Biogen Inc overvalued or undervalued?
Bullrun's valuation model currently marks Biogen Inc as 5.5% undervalued.
What is Biogen Inc's market cap?
Biogen Inc's market capitalization is USD 31.98B.
What is Biogen Inc's P/E ratio?
Biogen Inc's price-to-earnings (P/E) ratio is 23.2.
What does Biogen Inc do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy;